Financials
Financial year 2025
VAN DE PLAS PHARMA from Sint-Genesius-Rode, company number BE0437942825, closed financial year 2025 with a result of € -26,266 after tax. For that financial year VAN DE PLAS PHARMA recorded a gross margin of € 49,809 and equity of € 110,648. Compared with financial year 2024, the result moved from € 60,112 to € -26,266. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.
€ 110,648
▼ 19% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -26,266
▼ still € 60,112 profit in 2024
Profit after tax over the fiscal year.
€ 34,026
▼ 43% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 92,056.
People and assets in 2025
0.5
Average over the fiscal year, from the social balance sheet.
€ 38,142
▲ € 30,644 vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 226,120
▼ 9% vs 2024
€ 35,842 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 151,028
▲ 77% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,473
▲ € 4,447 vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 20,628 | € 68,864 | € 108,710 | € 49,809 | ▼ 54% |
| Profit after taxes | € -19,269 | € 28,702 | € 60,112 | € -26,266 | ▼ € 86,378 |
| Equity | € 48,099 | € 76,801 | € 136,914 | € 110,648 | ▼ 19% |
| Total debts | € 462,079 | € 412,341 | € 424,852 | € 455,703 | ▲ 7% |
| Cash | € 7,292 | € 14,816 | € 59,965 | € 34,026 | ▼ 43% |
| Land & buildings | € 192,761 | € 180,629 | € 168,496 | € 156,364 | ▼ 7% |
| Retained profit | € 29,507 | € 58,209 | € 118,322 | € 92,056 | ▼ 22% |
| Bank debt | € 269,101 | € 259,199 | € 248,059 | € 226,120 | ▼ 9% |
| Balance sheet total | € 510,178 | € 489,143 | € 561,766 | € 566,351 | ▲ 1% |
| Employees (FTE) | - | - | 0.5 | 0.5 |
Key figures of VAN DE PLAS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to VAN DE PLAS PHARMA?
What happened at VAN DE PLAS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 26,266 (▼ € 86,378 vs 2024). Source: NBB ↗
- New establishment in Sint-Genesius-Rode. KBO
- Start of the company according to the CBE. KBO
In short
From € 19,269 loss in 2022 to € 26,266 loss in 2025.
Paid € 2,855 in corporate taxes since 2022.
Best year ever: 2024, with € 60,112 profit.
A new publication or filing at VAN DE PLAS PHARMA? We notify you, reason included.
Follow VAN DE PLAS PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Van de plas - Merken comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
VAN DE PLAS PHARMABehind VAN DE PLAS PHARMA is Van de plas - Merken BV. The shares are held by Van de plas - Merken (100%).
Directors
According to the 2025 annual accounts
Director · represented by Van de Plas Jasmien
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Grote Hutsesteenweg 16
1640 Sint-Genesius-Rode
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARENET - Cloudflare, Inc., US
DNS
Cloudflare DNS
Website info
Features
Security
Network
Details
- Company number
- 0437.942.825
- VAT number
- BE 0437.942.825
- Registered office
- Grote Hutsesteenweg 16, 1640 Sint-Genesius-Rode
- Names & denominations
- VAN DE PLAS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 June 1989
- Peppol
- Active · Active since 24 Nov 2023
- Contact
- vandeplaspharma.be
- Activities · NACE
Apothekers
Detailhandel in farmaceutische producten